Patents by Inventor Marielle Chiron

Marielle Chiron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING
    Publication number: 20240034816
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
    Type: Application
    Filed: September 19, 2023
    Publication date: February 1, 2024
    Inventors: Nicolas GOURDIN, Laurent GAUTHIER, Alexandre TANG, Marielle CHIRON, Angela VIRONE-ODDOS, Alessandro MASIERO, Jochen BENINGA, Ingo FOCKEN, Sambasiva RAO, Yanfeng ZHOU, Leila SEVIGNY
  • MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123
    Publication number: 20230416383
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Application
    Filed: April 28, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON, Angela Virone-Oddos, Laurent Gauthier
  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20230416395
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: April 14, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123
    Patent number: 11692039
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: July 4, 2023
    Inventors: Marielle Chiron, Angela Virone-Oddos, Laurent Gauthier
  • Anti-CD38 antibodies and formulations
    Patent number: 11655302
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 23, 2023
    Assignee: SANOFI
    Inventors: Marielle Chiron Blondel, Cendrine Lemoine, Angela Virone-Oddos, Béatrice Cameron, Jacques Dumas, Alain Fournier, Jonathan Kingsbury, Brian Murray, Nathan Ostberg, Sanket Patke, Zichuan Zhang
  • MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123
    Publication number: 20220213202
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Application
    Filed: December 30, 2021
    Publication date: July 7, 2022
    Inventors: Céline AMARA, Céline NICOLAZZI, Marielle CHIRON, Francis DUFFIEUX, Jochen BENINGA, Angela VIRONE-ODDOS, Laurent GAUTHIER, Ariane THIELENS, Benjamin ROSSI
  • Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
    Patent number: 11208461
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 28, 2021
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
    Publication number: 20210293821
    Abstract: The present invention concerns the use of VCAM-1, ICAM-1 and/or PlGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 23, 2021
    Inventors: Jennifer DREYMANN, Caroline PACCARD, Marielle CHIRON-BLONDEL
  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER
    Publication number: 20200157181
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: October 24, 2019
    Publication date: May 21, 2020
    Inventors: Marielle CHIRON-BLONDEL, Diether LAMBRECHTS, Emmanuelle MAGHERINI, Vincent THUILLIER
  • IL-8 level based method of predicting the outcome of colon cancer treatment
    Patent number: 10501523
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: December 10, 2019
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20190275147
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: February 11, 2019
    Publication date: September 12, 2019
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
    Publication number: 20180113134
    Abstract: The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: January 25, 2017
    Publication date: April 26, 2018
    Inventors: Jennifer DREYMANN, Caroline PACCARD, Marielle CHIRON-BLONDEL
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER
    Publication number: 20170121387
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventors: Marielle CHIRON-BLONDEL, Diether LAMBRECHTS, Emmanuelle MAGHERINI, Vincent THUILLIER
  • Combinations of kinase inhibitors for the treatment of cancer
    Patent number: 9011863
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 21, 2015
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • Combinations of Kinase Inhibitors for the Treatment of Cancer
    Publication number: 20140271665
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Application
    Filed: July 8, 2011
    Publication date: September 18, 2014
    Applicants: Exelixis, Inc., Sanofi, Vanderbilt University
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20140127202
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: Aventis Pharma S.A.
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS
    Publication number: 20130330341
    Abstract: The invention relates to the treatment and the diagnosis of a group of patients bearing specific alleles of single nucleotide polymorphisms in the promoter region of the VEGFA gene. These patients are more responsive to Aflibercept and more likely to be efficiently treated by anti-VEGF therapy.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Applicant: SANOFI
    Inventors: Marielle Chiron Blondel, Emmanuelle Cousin, Jean-Francois Deleuze, Jennifer Dreymann, Sandrine Mace
  • Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
    Patent number: 8388963
    Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 5, 2013
    Assignees: Aventis Pharma SA, Regeneron Pharmaceuticals Inc
    Inventors: Patricia Vrignaud, Marielle Chiron-Blondel, Marie-Christine Bissery, Eric Furfine, Jocelyn Holash, Jesse M. Cedarbaum
  • Combination Comprising Combretastatin and Anticancer Agents
    Publication number: 20110054035
    Abstract: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 3, 2011
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marie-Christine BISSERY, Patricia VRIGNAUD, Marielle CHIRON-BLONDEL, Brigitte DEMERS